Cassava Sciences Inc. delivered its first set of data from a small study in Alzheimer's disease for PTI-125, its only remaining clinical-stage drug since the company changed its name from Pain Therapeutics Inc. in March. The small molecule, which has a novel mechanism of action in a disease that needs fresh treatment approaches, generated a 100% response rate in the 13-patient Phase II clinical trial and impacted all nine biomarkers assessed in the study.
Pain Therapeutics changed its name to Cassava as its focus shifted from the abuse-deterrent opioid Remoxy, which was rejected by the US Food and Drug Administration, to its early-stage Alzheimer's candidate PTI-125, which binds to misfolded versions of the protein filiman A (FLNA) to restore its normal shape and function. The National Institutes of Health have committed up to $6
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?